Clinical and Experimental Allergy最新文献

{"title":"Gender-Dependent Differences in Serum Osteopontin Levels in Chronic Spontaneous Urticaria: A Link to Disease Activity in Females","authors":"Hongshan Liu, Jiahua Guo, Jianing Yuan, Dan Ye, Ziyun Gao, Fujing Yang, Luyue Zhang, Songmei Geng, Weihui Zeng, Zhao Wang","doi":"10.1111/cea.70324","DOIUrl":"10.1111/cea.70324","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1097-1100"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Processionary Moth Exposure in Europe: Toxic–Irritant and Immunoglobulin E-Mediated Endotypes, Diagnosis and Management","authors":"Prasad Dasari,&nbsp;Josefine Haas,&nbsp;Wolfgang Rohe,&nbsp;Kai Gloyna,&nbsp;Christoph Viebahn,&nbsp;Susann Forkel,&nbsp;Michael Szardenings,&nbsp;Christine Stadelmann,&nbsp;Michael P. Schön,&nbsp;Timo Buhl","doi":"10.1111/cea.70415","DOIUrl":"10.1111/cea.70415","url":null,"abstract":"<p>Processionary moths (<i>Thaumetopoea</i> spp.), particularly the oak processionary moth (<i>Thaumetopoea processionea</i>), are an increasingly relevant cause of allergic and toxic disease in Europe, occurring in the context of reported range expansion, changing environmental conditions and persistent contamination with airborne urticating hairs (setae). Clinical manifestations range from toxic–irritant dermatitis and ocular injury to respiratory symptoms, while a subset of exposed individuals develops genuine IgE-mediated disease, including rhinoconjunctivitis, asthma, and rare cases of anaphylaxis. These presentations reflect two mechanistically distinct endotypes: (i) toxin-driven epithelial penetration by the urticating hairs with neuro-inflammatory activation and (ii) allergen-specific sensitisation to defined molecular components such as Tha p 1 and Tha p 2. Accurate endotype differentiation is clinically relevant, as symptom latency, severity, and risk of systemic progression differ substantially. Diagnostic evaluation relies on exposure history and phenotype recognition, complemented in selected cases and experienced centres by skin testing using research-grade extracts and emerging component-resolved approaches. Basophil activation testing may provide additional mechanistic insights in selected cases. Management comprises prompt decontamination, anti-inflammatory therapy, urgent ophthalmologic assessment when eye involvement is suspected, and guideline-based management of anaphylaxis. The environmental persistence of setae and recurrent seasonal exposure highlight the need for improved surveillance, validated molecular diagnostics, and translational research defining immune mechanisms and biomarkers.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1017-1030"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Meta-Analysis of Anti-Thyroid Peroxidase Antibody and Omalizumab Response in Chronic Spontaneous Urticaria","authors":"Ju Hyun Lee,&nbsp;Min Jung Geum,&nbsp;Do-Young Kim,&nbsp;Young-Mi Ah,&nbsp;Yun Mi Yu","doi":"10.1111/cea.70363","DOIUrl":"10.1111/cea.70363","url":null,"abstract":"&lt;p&gt;Chronic spontaneous urticaria (CSU) is a chronic immune-mediated skin disorder characterized by the idiopathic occurrence of wheals, angioedema, or both for more than six weeks [&lt;span&gt;1&lt;/span&gt;]. It affects approximately 0.1%–1.5% of the population and significantly reduces quality of life [&lt;span&gt;2&lt;/span&gt;]. Second-generation H1-antihistamines are recommended as first-line therapy; however, a subset of patients remains symptomatic and requires escalation to omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody. Considering its high cost and highly variable treatment response, reliable predictive biomarkers are needed to ensure a more targeted therapy.&lt;/p&gt;&lt;p&gt;Thyroid autoimmunity has emerged as a possible factor influencing treatment response in CSU [&lt;span&gt;3&lt;/span&gt;]. Anti-thyroid peroxidase (anti-TPO) antibodies are more frequently detected in patients with CSU and have been linked to an autoimmune subtype known as type IIb CSU that may be less responsive to omalizumab [&lt;span&gt;3&lt;/span&gt;]. However, existing studies have shown conflicting results [&lt;span&gt;4-6&lt;/span&gt;], and the predictive value of anti-TPO status has not been systematically evaluated.&lt;/p&gt;&lt;p&gt;We conducted a systematic review and meta-analysis to evaluate the association between thyroid autoimmunity and clinical response to omalizumab in patients with CSU, focusing on anti-TPO antibody status and other relevant biomarkers, including IgE and C-reactive protein (CRP). The MEDLINE, Embase, CENTRAL, SCOPUS, and Web of Science databases were systematically searched for relevant studies published from inception through March 1, 2026 (PROSPERO CRD420251148223). Eighteen cohort studies comprising 1846 patients were included. Detailed methods and additional analyses are available in the Open Science Framework (OSF) repository at https://doi.org/10.17605/OSF.IO/49VXA.&lt;/p&gt;&lt;p&gt;Patients without anti-TPO positivity exhibited a significantly higher likelihood of responding to omalizumab compared to those with anti-TPO positivity (OR 3.25, 95% CI 1.53–6.91). In subgroup analyses by region and income, no significant differences were observed between groups (&lt;i&gt;p&lt;/i&gt; = 0.62 for region, &lt;i&gt;p&lt;/i&gt; = 0.35 for income). Additionally, a significant association between anti-TPO status and omalizumab response was confirmed in the group excluding low-income countries (Table 1). Meta-regression analyses consistently indicated that age, sex, disease duration, baseline CSU severity, and concomitant angioedema did not significantly influence the association. These findings remained robust in sensitivity analyses, including when treatment response was redefined as well-controlled disease (OR 2.32, 95% CI 1.13–4.74) and after excluding a study with heterogeneous anti-TPO cutoff (OR 4.18, 95% CI 2.13–8.18). However, no significant association was observed between baseline anti-TPO levels and the response to omalizumab (MD –0.05 IU/mL, 95% CI –34.07 to 33.96). In pooled analyses of response rates including single-arm s","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1104-1106"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70363","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148161943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Patient and Public Involvement Reporting in Allergy Prevention Trials: The Example of Complementary Feeding","authors":"Jonas Lander,&nbsp;Helen Elizabeth Smith,&nbsp;Johanna Meyer,&nbsp;Theresa Donhauser,&nbsp;Christian Apfelbacher","doi":"10.1111/cea.70343","DOIUrl":"10.1111/cea.70343","url":null,"abstract":"&lt;p&gt;Clinical research is essential to uphold and improve health, but patient representatives have long criticized trials for focusing on clinical outcomes rather than patient priorities even if a gradual shift towards quality of life aspects is now visible [&lt;span&gt;1&lt;/span&gt;]. Similar discussions have emerged in allergy research [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Patient and public involvement (PPI), an approach in which research is conducted with rather than on or for patients, has been recognized and internationally advocated for over two decades. Respective developments have been identified since the early 2000s [&lt;span&gt;3&lt;/span&gt;]. Since the late 2000s, PPI became a more formal part of research systems, guideline development and national research strategies (e.g., [&lt;span&gt;4, 5&lt;/span&gt;]), accompanied by increasing empirical and conceptual literature (e.g., [&lt;span&gt;6&lt;/span&gt;]). Since mid-2010, practical tools to help integrate PPI in research practice are widely available, including dedicated guidance, evaluation tools and reporting frameworks (e.g., [&lt;span&gt;7&lt;/span&gt;]).&lt;/p&gt;&lt;p&gt;In allergy prevention research, PPI could add value at several points of a trial: co-setting priorities and outcomes (e.g., symptom relief, sleep, parental anxiety); co-designing real-life interventions (e.g., feeding routines); tailoring risk communication (e.g., parents with high risk infants); optimizing recruitment beyond tertiary clinics; and co-creating post-trial messages for primary care. However, it is unclear to which degree such efforts have been implemented in allergy research.&lt;/p&gt;&lt;p&gt;We assessed the reporting of PPI in clinical trials on complementary feeding (CF) as an example. CF trials typically examine the timing and composition of infant diet, such as the early introduction of peanut or egg. CF interventions constitute a key domain in early allergy prevention that directly affects parental decision-making. Therefore, we used CF trials to assess if PPI is visible in a domain where parental practices are central to intervention delivery.&lt;/p&gt;&lt;p&gt;The included trials were derived from an up-to-date overview of systematic reviews on early allergy prevention by Kuper et al. [&lt;span&gt;8&lt;/span&gt;]. The study systematically identified and synthesized randomized CF trials and thus represents the most recent evidence base. We included all identified trials published since 2000 to examine how the increasing international visibility of PPI is reflected in published CF trials.&lt;/p&gt;&lt;p&gt;We used the main themes of the GRIPP2 reporting checklist—developed in 2011 and revised in 2017 [&lt;span&gt;7&lt;/span&gt;]—for PPI in research as an analytical framework to identify whether PPI-related elements were visible in trial reports. We defined and pre-tested a structured set of &lt;i&gt;n&lt;/i&gt; = 10 data extraction categories in relation to: PPI context: general consideration of patient-public perspectives on research, need for patient-centred research; PPI concept: importance of PPI concept, related PPI concepts (e.g., shared-de","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1114-1116"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70343","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147970972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Comment on 'Effects of Acupuncture as a Therapeutic Intervention Targeting Both Skin and Gastrointestinal Symptoms in Patients With Atopic Dermatitis: A Randomised Controlled Trial'.","authors":"Kyuseok Kim, Jundong Kim, Soon-Kyeong Kwon, Hi-Joon Park","doi":"10.1111/cea.70394","DOIUrl":"10.1111/cea.70394","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":"1146-1148"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Risk Factors of Dupilumab-Associated Head and Neck Dermatitis in Patients With Atopic Dermatitis","authors":"Zifan Li,&nbsp;Ruoxi Yu,&nbsp;Hongxiang Chen,&nbsp;Ying Lin","doi":"10.1111/cea.70354","DOIUrl":"10.1111/cea.70354","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1090-1092"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Type 2 Inflammation: Why Neutrophils Deserve a Central Role in Refractory Airway Disease","authors":"Yuzhe Hao,&nbsp;Yue Zhou,&nbsp;Jianjun Chen","doi":"10.1111/cea.70412","DOIUrl":"10.1111/cea.70412","url":null,"abstract":"&lt;p&gt;The concept of united airway disease has reshaped the way clinicians and researchers understand chronic inflammatory disorders of the upper and lower airways. Together with the development of biologics targeting Type 2 inflammation, this concept has reinforced the central role of eosinophilic immunity in asthma, allergic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP). For many patients, Type 2-directed treatment has improved symptom control, reduced exacerbations and, in some patients, altered the clinical trajectory of severe airway disease [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;However, the success of the Type 2 paradigm has also exposed its limitations. A substantial proportion of patients continue to experience persistent symptoms, recurrent disease, progressive tissue remodelling or corticosteroid hyporesponsiveness despite receiving appropriate treatment, including Type 2-directed therapies. These patients often show neutrophil-predominant or mixed inflammatory patterns, together with sustained activation of innate immune pathways. Such observations suggest that refractory airway disease cannot be explained simply by insufficient control of eosinophilic inflammation [&lt;span&gt;2-4&lt;/span&gt;]. Although corticosteroids effectively suppress several components of airway inflammation, they do not uniformly control neutrophil-rich inflammatory programmes.&lt;/p&gt;&lt;p&gt;The next challenge is therefore not to replace the Type 2 paradigm, but to complement it. A more complete understanding of refractory airway disease requires attention to non-Type 2 immune mechanisms, especially those linking epithelial stress, innate immune activation and neutrophil-mediated inflammation. In this context, neutrophils deserve renewed attention, not only as markers of severe inflammation, but also as active regulators of persistent airway disease. This perspective does not imply that airway inflammation alone accounts for bronchial smooth muscle hyperresponsiveness in asthma; rather, it focuses on how inflammatory programmes amplify disease severity and treatment refractoriness. Although COPD is another important neutrophil-associated chronic airway disease, this Editorial focuses primarily on asthma, allergic rhinitis and CRSwNP in keeping with its emphasis on the united airway concept and the limitations of Type 2-directed treatment.&lt;/p&gt;&lt;p&gt;Neutrophils have traditionally been regarded as short-lived effector cells recruited in response to infection, tissue injury or severe inflammation. In this view, increased neutrophil numbers in airway samples mainly reflect disease severity rather than directly shaping disease progression. This interpretation is increasingly insufficient. Recent advances in single-cell transcriptomics, spatial profiling and multi-omics analyses have shown that airway neutrophils are not a homogeneous cell population, but exist in multiple functional states shaped by the local tissue environment [&lt;span&gt;4, 5&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Functionally reprogrammed neutroph","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"994-997"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital-Based Food Challenges for the Diagnosis of Food Allergy—A BSACI Clinical Practice Statement","authors":"I. J. Skypala,&nbsp;H. B. Ball,&nbsp;C. Gore,&nbsp;K. Sooriyakumar,&nbsp;D. Stevens,&nbsp;V. Patil,&nbsp;A. Elghoudi,&nbsp;J. Dempsey,&nbsp;S. Blamires,&nbsp;K. Wright,&nbsp;K. Stoenchev,&nbsp;M. Doyle,&nbsp;N. Gunawardana,&nbsp;L. Siew,&nbsp;R. Knibb,&nbsp;J. Edmonds,&nbsp;N. Patel","doi":"10.1111/cea.70406","DOIUrl":"10.1111/cea.70406","url":null,"abstract":"<div>\u0000 \u0000 <p>Food challenges play an important role in the diagnosis and management of food hypersensitivity. Although the gold-standard is the double-blind, placebo-controlled food challenge, an open challenge, where the challenge food is known to both the patient and the allergy team, is a practical and effective tool for use in daily clinical practice. A food challenge can help determine the presence or absence of a food allergy if the history and allergy tests are discordant, or if resolution of the allergy is expected. The outcome of a food challenge can result in either confident introduction or re-introduction of foods or provide clarity on which foods or forms of the food need to be avoided. Challenges can be a positive or negative experience for individuals; to maximise the potential for positive impact, food challenges should be overseen by individuals with relevant knowledge, skills and experience, and take place in a suitable clinical area with appropriate access to emergency support and a pathway for admission to an inpatient facility. Challenge foods should be age-specific, in an appropriate form (uncooked, cooked, baked, composite food), and given in incrementally increasing amounts until an age-specific top or cumulative dose has been consumed. The decision to pause or stop a challenge should be based on international guidance and clinician judgement, but also consider an individual's symptom history and their preferences.</p>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1001-1016"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Eosinophil-Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis","authors":"J. I. Olydam,&nbsp;S. Sengkerij,&nbsp;S. Veenbergen,&nbsp;D. J. Hijnen","doi":"10.1111/cea.70338","DOIUrl":"10.1111/cea.70338","url":null,"abstract":"&lt;p&gt;Eosinophils play a key role in atopic diseases and blood eosinophil counts are being used as a predictive biomarker for asthma subtype and treatment response [&lt;span&gt;1&lt;/span&gt;]. However, the role of eosinophils and their mediators in atopic dermatitis (AD) remains unclear. Eosinophil-derived neurotoxin (EDN) is a granule protein released by activated eosinophils. The association between serum EDN levels and AD has been explored to a limited extent [&lt;span&gt;2, 3&lt;/span&gt;] The aim of this study was to investigate the effect of ciclosporine A (CsA) treatment on serum EDN levels and to evaluate its potential as a biomarker for treatment response in AD.&lt;/p&gt;&lt;p&gt;This prospective, observational, open-label study enrolled 40 adults with moderate-to-severe AD experiencing a disease flare. All participants received oral CsA 3–5 mg/kg/day. The study was approved by the Erasmus Medical Center ethics committee (MEC-2019-0517; NL70997.078.19), and all patients provided written informed consent. Nine non-atopic, non-smoking healthy controls were included. Clinical and patient-reported outcome measures were obtained at baseline and week 4. Serum EDN was measured using ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden), according to the manufacturer's instruction. All statistical data were analysed using IBM SPSS Statisticsv25.0 and GraphPad Prism10. Continuous variables were summarized as medians. Paired data were analysed with the Wilcoxon signed-rank test; categorical variables with Fisher's exact test. Correlations were assessed with Spearman's rank test. Patients were classified in ‘good responders’ versus ‘responders’ based on 80% reduction in EASI-score based on the clinical expected treatment effect.&lt;/p&gt;&lt;p&gt;Forty patients with moderate-to-severe AD (median age 29.5 (IQR 25.0–35.8)) experiencing a disease flare were included in this study. Mild asthma (GINA 1–2 (42.5%)), allergic contact dermatitis (27.5%), and allergic (rhino)conjunctivitis (72.5%) were reported. CsA treatment led to a significant decrease in disease severity after 4 weeks of treatment. The median EASI score at baseline was 22.2 (IQR 19.0–32.1) and significantly decreased to 4.9 (IQR 3.6–6.8) at week 4 (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). Seventeen patients (43.6%) reached an IGA score of 0 or 1 at week 4. At week four, EASI-50 and EASI-75 were achieved by 97% (38/40) and 55.8% (21/40) of the patients, respectively. The healthy controls (&lt;i&gt;n&lt;/i&gt; = 9) were non-atopic, non-smokers with a median age of 47 (IQR 28.5–55.5) and all female.&lt;/p&gt;&lt;p&gt;Serum EDN levels were significantly increased (54.3 ng/mL (IQR 27.2–121.0)) in AD patients compared with healthy controls (24.4 μg/L (IQR 17.5–34.5)) (p &lt; 0.0015) Figure 1A. High and low serum EDN levels were defined as ≥ or ≤ than median EDN level (54.3 μg/L) in this AD cohort. There were no significant differences in baseline patient characteristics and disease severity between the AD patients with high or low serum EDN.&lt;/p&gt;&lt;p&gt;EDN levels significantly decreased af","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1084-1086"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70338","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147926939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variants at 8p21.3 Mediate BMP1 Expression, Contributing to Higher Atopic Dermatitis Risk","authors":"Jia Yi Karen Wong,&nbsp;Yang Yie Sio,&nbsp;Yi Ying Eliza Lim,&nbsp;Yee-How Say,&nbsp;Kavita Reginald,&nbsp;Fook Tim Chew","doi":"10.1111/cea.70332","DOIUrl":"10.1111/cea.70332","url":null,"abstract":"&lt;p&gt;Atopic dermatitis (AD) is a chronic inflammatory skin disorder in which epidermal barrier dysfunction and immune dysregulation jointly drive disease susceptibility and progression [&lt;span&gt;1&lt;/span&gt;]. While these mechanisms have been extensively studied, increasing literature highlights the roles of extracellular matrix (ECM) components, particularly collagens, in AD [&lt;span&gt;2&lt;/span&gt;]. AD patients have been reported to exhibit lower type I and type III collagen expression in the skin compared to healthy individuals [&lt;span&gt;3&lt;/span&gt;], while lesions featured reduced type IV collagen and a thinner basement membrane [&lt;span&gt;4&lt;/span&gt;]. These studies suggest that disruptions in collagen composition may compromise barrier integrity, facilitating allergen/irritant penetration [&lt;span&gt;3, 5&lt;/span&gt;]. Bone morphogenetic protein 1 (BMP1) is a secreted metalloprotease known for its pivotal role in ECM assembly, where it cleaves carboxyl-terminal propeptides of procollagens to produce mature collagen fibrils, thereby maintaining the structural integrity of connective tissues [&lt;span&gt;6&lt;/span&gt;]. In murine models, &lt;i&gt;BMP1&lt;/i&gt; deficiency led to thinned and fragile skin with reduced mechanical strength [&lt;span&gt;6&lt;/span&gt;]. Despite its central role in skin biology, BMP1 has received little attention in the context of chronic skin diseases. This study evaluates the potential involvement of BMP1 in AD pathogenesis by (i) profiling &lt;i&gt;BMP1&lt;/i&gt; expression in peripheral blood mononuclear cells (PBMCs) from participants of the Singapore/Malaysia Cross-Sectional Genetic Epidemiology Study (SMCGES), (ii) identifying proximal cis-regulatory variants at 8p21.3 affecting &lt;i&gt;BMP1&lt;/i&gt; expression, (iii) functionally validating promoter activity and (iv) assessing the relationship between &lt;i&gt;BMP1&lt;/i&gt; and skin barrier function.&lt;/p&gt;&lt;p&gt;We analysed participants of Chinese ethnicity from the SMCGES. Details of participant recruitment have been reported previously [&lt;span&gt;7&lt;/span&gt;]. Two independent cohorts were used (Repository Table S1): a transcriptome-profiled cohort in which PBMCs were collected for whole-transcriptome sequencing and single nucleotide polymorphism (SNP) genotyping (&lt;i&gt;n&lt;/i&gt; = 518; Age = 22.8 ± 7.2; 52.3% females), and a genotyped cohort that provided buccal cells for SNP genotyping (&lt;i&gt;n&lt;/i&gt; = 2742; Age = 22.7 ± 6.2; 65.0% females). AD status was determined using validated diagnostic guidelines (Hanifin and Rajka, and the UK Working Party criteria) and sensitisation to common house dust mites assessed by skin prick testing (SPT). Individuals were classified as having AD if they reported an itchy rash lasting or recurring for at least 6 months affecting flexural areas, and had a positive SPT response (wheal diameter ≥ 3 mm) to &lt;i&gt;Dermatophagoides pteronyssinus&lt;/i&gt; or &lt;i&gt;Blomia tropicalis&lt;/i&gt;. Participants who reported no symptoms of AD and exhibited a negative SPT response were classified as non-AD controls. AD cases were further stratified by severity based on sleep disturban","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1080-1083"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70332","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}